Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Cash from Financing Activities data on record, last reported at $5.9 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 98.3% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $13.7 million, down 96.13%, while the annual FY2025 figure was $13.7 million, 96.13% down from the prior year.
  • Cash from Financing Activities reached $5.9 million in Q4 2025 per SNDX's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $347.4 million in Q4 2024 and bottomed at -$13.5 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $46.1 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 893.26% in 2022, then soared 344.17% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $109.8 million in 2021, then surged by 48.94% to $163.5 million in 2022, then soared by 58.09% to $258.5 million in 2023, then skyrocketed by 34.41% to $347.4 million in 2024, then crashed by 98.3% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $5.9 million in Q4 2025, $6.3 million in Q3 2025, and $551000.0 in Q2 2025.